News from oncogenex pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 01, 2017, 17:25 ET Achieve Life Sciences Announces Closing of Merger with OncoGenex Pharmaceuticals

Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced the closing of its previously announced merger with OncoGenex Pharmaceuticals, as a result ...

Jun 13, 2017, 16:30 ET Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC

Achieve Life Sciences, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (OncoGenex) today announced that the Registration Statement...

May 15, 2017, 08:00 ET OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2017

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced financial results for the first quarter ended March 31, 2017. Recent Events In January ...

May 09, 2017, 09:00 ET OncoGenex to Report First Quarter 2017 Financial Results on May 15, 2017

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2017 financial results on Monday, May 15, 2017....

Mar 08, 2017, 08:00 ET Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")

Achieve Life Sciences, Inc. ("Achieve"), and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) ("OncoGenex") today announced that the Society for...

Mar 01, 2017, 08:00 ET Achieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National Institutes of Health to Advance the Development of Cytisine for Smoking Cessation

Achieve Life Science, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (OncoGenex) today announced a strategic collaboration with...

Feb 23, 2017, 08:00 ET OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its year end 2016 financial results. Recent Events In January 2017, OncoGenex, and...

Feb 21, 2017, 08:00 ET OncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that apatorsen results from two randomized Phase 2 clinical trials were presented at...

Feb 16, 2017, 15:01 ET OncoGenex to Report Year End 2016 Financial Results on Feb. 23, 2017

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its year end 2016 financial results on Thursday, Feb. 23, 2017....

Jan 05, 2017, 04:30 ET OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement

ncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) ("OncoGenex"), a publicly held oncology biopharmaceutical company, and Achieve Life Science, Inc....

Nov 10, 2016, 04:01 ET OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2016

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its third quarter 2016 financial results. Recent Events In November 2016, the company...

Nov 03, 2016, 04:01 ET OncoGenex to Report Third Quarter 2016 Financial Results on Nov. 10, 2016

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its third quarter 2016 financial results on Thursday, Nov. 10,...

Oct 25, 2016, 05:00 ET OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2™ Trial in Metastatic Bladder Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today positive survival results from the final analysis of the Phase 2 Borealis-2™ trial of...

Oct 13, 2016, 07:30 ET OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from the final analysis of the Phase 3 ENSPIRIT trial of custirsen in patients ...

Aug 16, 2016, 07:00 ET OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today results from the final analysis of AFFINITY, the Phase 3 trial of custirsen in men...

Jul 21, 2016, 04:01 ET OncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its second quarter 2016 financial results on Thursday, August 4,...

May 12, 2016, 04:01 ET OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2016

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter 2016 financial results and provided a summary of anticipated...

Apr 28, 2016, 04:01 ET OncoGenex to Report First Quarter 2016 Financial Results on May 12, 2016

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its first quarter 2016 financial results on Thursday, May 12, 2016....

Apr 05, 2016, 04:02 ET OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that John Bencich, Chief Financial Officer at OncoGenex, will present at the 15th...

Mar 09, 2016, 04:01 ET OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2015

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced year end 2015 financial results and provided a summary of anticipated milestones....

Feb 24, 2016, 04:01 ET OncoGenex to Report Fourth Quarter and Year End 2015 Financial Results on March 9, 2016

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it will report its fourth quarter and year-end 2015 financial results on...

Feb 04, 2016, 04:01 ET OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it is implementing a plan to reduce operating expenses, including a workforce...

Jan 20, 2016, 04:01 ET OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data from the Phase 2 Spruce™ trial evaluating the combination of apatorsen with...

Dec 09, 2015, 07:00 ET OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the independent Data Safety Monitoring Board (DSMB) at Dana-Farber/Harvard Cancer ...

Dec 01, 2015, 04:01 ET OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses

Following an independent Data Monitoring Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that its Phase 3...